The Women's Interagency HIV Study (WIHS), established in 1993, is a multi-center, prospective, observational cohort study of women living in the United States who are either HIV-infected or at risk for HIV acquisition. WIHS plays an important role in NIAID’s effort to understand the current epidemiology of HIV infection, disease progression, treatment use and outcomes, and related co-morbidities among U.S. residents with HIV. Understanding differences in HIV disease and treatment outcomes between women compared to men, and in different racial and ethnic groups, is a critical public health goal. The WIHS is currently conducted at ten clinical research sites (CRSs), each of which is representative of the population of HIV-infected women in or out of care within their geographical region. This clinical research consortium is an integral part of the NIAID portfolio of research on HIV in women.
Main Areas of Focus
- To understand the current epidemiology of HIV infection, disease progression, treatment use and outcomes, and related co-morbidities among HIV-positive individuals in the United States
- To understand the differences in HIV disease and treatment outcomes between women compared to men and in different racial and ethnic groups
- To further understanding on how to achieve optimal therapy effectiveness
- To study the uptake of antiretroviral medications
- To study the predictors of successful and sustained viral suppression
- To conduct research to define the clinical outcomes for women with HIV across their full lifespan
The WIHS Executive Committee (EC) is responsible for managing the overall scientific aims of the WIHS and is composed of the Principal Investigators (PIs) from each awardee institution, a WIHS community advisory board member selected by study subjects to represent their interests, and a Project Scientist from each current co-funding NIH Institute.